Formosa Pharmaceuticalsincis A Clinical Stagebiopharmaceutical Company Based In Taiwanfocusing On Developing Drug Candidates In Ophthalmologyoncologyand Anti Infectivesthecompany Is Listed On Thetaiwan Stock Exchangeunder Theticker Tpe68 8 Formosa Leverages Its Proprietary Activepharmaceutical Nanoparticletechnologyapnta To Createinnovativedrug Delivery Systemsparticularly For Ophthalmic Applicationstheir Lead Productapp1 007Is A Us Fda Approved Ophthalmic Nanosuspension Designed To Providerapid Anti Inflammatory And Pain Relief After Cataract Surgeryin Oncologyformosa Is Developing Tsy 0110A Biosimilar For Her2 Positivebreast Canceras Part Of Its Focus On Antibody Drug Conjugatebiosimilars And Small Moleculenew Chemical Entitiesthecompany Also Explores Theuseof Its Apntatechnology In Anti Infectivedrug Development Formosa Pharmaceuticals Actively Collaborates With Global Partners To Enhanceits Pipelineand Expand Its Capabilities In Thebiopharmaceutical Sector
